Genentech USA, Inc.
Genentech USA, Inc., a pioneering biotechnology company, is headquartered in South San Francisco, California. Founded in 1976, Genentech has established itself as a leader in the biopharmaceutical industry, focusing on the development of innovative therapies for serious medical conditions, particularly in oncology, immunology, and neuroscience.
With a commitment to research and development, Genentech has introduced groundbreaking products such as Herceptin and Avastin, which have transformed treatment protocols for various cancers. The company is renowned for its robust pipeline and dedication to personalised medicine, setting it apart in a competitive market.
Recognised for its contributions to healthcare, Genentech has received numerous accolades, solidifying its position as a key player in the biotechnology sector. Its ongoing commitment to scientific advancement continues to drive its success and influence in the industry.
+45 vs industry average
Genentech USA, Inc.’s score of 85 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Genentech USA, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Genentech USA, Inc. yet.
Genentech USA, Inc.'s reported carbon emissions
Genentech USA, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Roche Holding AG, which influences its climate commitments and emissions reporting.
As part of its parent company's sustainability initiatives, Genentech adheres to reduction targets and climate strategies set by Roche Holding AG. These initiatives include commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), both of which are cascaded from Roche. However, specific reduction targets or achievements for Genentech itself have not been disclosed.
While no absolute emissions figures are provided, Genentech's alignment with Roche's broader climate strategies indicates a commitment to addressing carbon emissions and enhancing sustainability practices within the pharmaceutical industry.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Genentech USA, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Genentech USA, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisationsNo peer comparison is available for Genentech USA, Inc. yet.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project